Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29627917 | 0.84 | ABL1 (0.36) | ACACBABL1TRPV1ACHEROCK2 | |
| Trifluoroacetic Acid SCHEMBL29908226 | 0.83 | ACACB (0.40) | ACACBTRPV1GRIN1ROCK2ROCK1 | |
| Trifluoroacetic Acid SCHEMBL29627947 | 0.81 | ROCK2 (0.42) | ABL1TRPV1ROCK2ROCK1 | |
| Trifluoroacetic Acid SCHEMBL29628004 | 0.81 | ROCK2 (0.37) | ACACBROCK2 | |
| SCHEMBL29908262 | 0.81 | ROCK2 (0.39) | HTR1AGRIN1ROCK2ROCK1 | |
| Trifluoroacetic Acid SCHEMBL29627872 | 0.80 | ACACB (0.38) | ACACBABL1TRPV1ROCK2 | |
| SCHEMBL29908257 | 0.79 | GRIN2B (0.41) | HTR1AROCK2ROCK1 | |
| SCHEMBL29908225 | 0.79 | KCNH2 (0.43) | ABL1HTR1ATRPV1ROCK2ROCK1 | |
| SCHEMBL29627924 | 0.79 | PIK3CA (0.40) | HTR1AROCK2ROCK1 | |
| SCHEMBL29627972 | 0.78 | ROCK2 (0.38) | HTR1AGRIN1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | disclosed |
| EP-4003340-A2 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, CIT | ACACB 1634/4885ABL1 236/4885HTR1A 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.